解除与传奇生物合并收益32亿美元 金斯瑞2024年扭亏为盈

新京报
13 Mar

3月12日,金斯瑞生物科技(简称“金斯瑞”)发布2024年全年财务业绩,报告期内公司持续经营业务的收益为5.95亿美元,同比增长6.1%;拥有人应占利润为29.62亿美元,上年同期亏损约9547.7万美元。扭亏的原因主要是与传奇生物解除合并获得约32亿美元收益所致。  对于2024年持续经营业务营收增长的原因,金斯瑞表示,主要是持续投入商业推广,业务品牌知名度增加,以及推出新的竞争性服务和产品带来...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10